A Bioequivalence Study of Two Formulations of Ezetimibe and Atorvastatin in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of **ezetimibe/atorvastatin** in healthy volunteers. Bioequivalence studies are crucial in determining whether different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, ensuring therapeutic equivalence. This is clinically relevant as it ensures that patients receive the same therapeutic benefits and safety profile from different formulations of the same medication.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet or physical activity are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of ezetimibe/atorvastatin in **healthy volunteers**. This study is a Phase 2 trial, categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is August 30, 2023, with an anticipated end date of November 20, 2023. The trial will involve a series of study visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive one of the two formulations under investigation.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the pharmacokinetic parameters of the formulations. These visits are crucial for ensuring participant safety and collecting data necessary for evaluating the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on the study's completion.

The expected length of participant involvement is approximately three months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are structured to maintain scientific rigor while ensuring the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include any additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on August 30, 2023, with an estimated end date of November 20, 2023. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The efficacy parameters will be measured at various timepoints throughout the study, utilizing appropriate tools and instruments to ensure accuracy and reliability. The data collected will be analyzed to determine the efficacy of the intervention under investigation.